A powerful new painkiller with no apparent side effects or addictive qualities, may now be only a year or two from the consumer market.

"This offers a major paradigm shift in the control of pain," declares Dr. Simon Halegoua, Professor of Neurobiology & Behavior at Stony Brook University, who has identified a novel sodium ion channel involved in the transmission of pain.

Phase II Clinical trials are currently underway in England and Canada.

(READ the story in ScienceDaily)